← Back to Search

Tyrosine Kinase Inhibitor

Cabozantinib for Non-Small Cell Lung Cancer

Phase 2
Recruiting
Led By Alexander Drilon, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The subject has a Karnofsky performance status of > 70%
The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document
Must not have
The subject has experienced clinically-significant hematemesis or gastrointestinal bleeding, clinically-significant hemoptysis, radiographic evidence of cavitating pulmonary lesion(s), tumor in contact with invading major blood vessels, or evidence of an endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib
Prior treatment with cabozantinib
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Summary

This trial will help us understand if cabozantinib can help patients with gene RET, ROS1, or NTRK fusion or increased MET or AXL activity by inhibiting these genes that lead to lung cancer cell growth.

Who is the study for?
Adults with advanced non-small cell lung cancer that is metastatic or unresectable and have specific genetic changes (RET, ROS1, NTRK fusions, MET or AXL overexpression/amplification/mutation). Must be able to perform daily activities well (Karnofsky >70%), have good organ function, not pregnant, agree to use contraception. Excludes those with recent significant illnesses/treatments or known allergies to cabozantinib.Check my eligibility
What is being tested?
The trial tests the effects of an oral drug called Cabozantinib on patients with certain gene changes in their lung cancer cells. It's a phase II study which means it focuses on how effective this treatment is and monitors side effects closely.See study design
What are the potential side effects?
Cabozantinib may cause side effects like tiredness, digestive issues such as diarrhea and nausea, high blood pressure, hand-foot skin reactions, weight loss and decreased appetite. Some rare but serious side effects include bleeding or holes in the stomach/intestine.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am able to care for myself and engage in normal activities.
Select...
I understand the study requirements and have signed the consent form.
Select...
I am 18 years old or older.
Select...
My cancer has specific genetic changes like KIF5B/RET, NTRK, MET, AXL, or ROS1.
Select...
I am a woman who can have children and my pregnancy test was negative.
Select...
I agree to use contraception if I'm sexually active.
Select...
My lung cancer cannot be removed by surgery and has spread.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had serious bleeding or a tumor affecting major blood vessels in the last 28 days.
Select...
I have been treated with cabozantinib before.
Select...
I haven't had radiation for bone or brain cancer, or any radiation treatment, in the last 2 to 4 weeks.
Select...
I have recovered from previous treatment side effects, except for hair loss.
Select...
I have untreated and symptomatic brain metastases.
Select...
I do not have any major health issues or surgeries that could interfere with the study.
Select...
I haven't taken any cancer drugs in the last 3 weeks or within 5 half-lives of the drug.
Select...
I need to take blood thinners or medication to prevent blood clots.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
objective response rate (ORR) (Group A)
objective response rate (ORR) (Group B)
Secondary outcome measures
overall survival (OS) (Group A)
overall survival (OS) (Group B, C & D)
progression-free survival (PFS) (Group A)
+2 more
Other outcome measures
objective response rate (ORR) (Group D)

Side effects data

From 2022 Phase 2 trial • 45 Patients • NCT02101736
95%
HYPOTHYROIDISM
73%
DIARRHEA
55%
WEIGHT LOSS
50%
FATIGUE
41%
NAUSEA
41%
ASPARTATE AMINOTRANSFERASE INCREASED
41%
VOMITING
41%
ANOREXIA
41%
ALANINE AMINOTRANSFERASE INCREASED
41%
Neutrophil Count Decreased
36%
PAIN IN EXTREMITY
36%
HEADACHE
36%
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME
36%
HYPERTENSION
32%
PAIN
32%
PROTEINURIA
27%
ABDOMINAL PAIN
27%
White Blood Cell Count Decreased
23%
Skin Hypopigmentation
23%
Platelet Count Decreased
23%
HAIR COLOR CHANGE
23%
Renal & Urinary Disorders - Other, Ketonuria
23%
PLATELET COUNT DECREASE
23%
HYPONATREMIA
23%
Decreased Platelet Count
18%
HYPOPHOSPHATEMIA
18%
HYPOKALEMIA
18%
Alopecia
18%
Hyperkalemia
18%
Upper Respiratory Infection
18%
HEMOGLOBIN INCREASED
14%
BILIRUBIN INCREASED
14%
DIZZINESS
14%
Pruritis
14%
ACNEIFORM RASH
14%
Fever
14%
Rash Maculopapular
14%
CONSTIPATION
14%
HYPERGLYCEMIA
14%
HYPOGLYCEMIA
14%
Blood Bilirubin Increased
14%
Cough
14%
Rash Acneiform
14%
Skin And Subcutaneous Disorders - Other, Achromotricia
9%
TUMOR PAIN
9%
ORAL PAIN
9%
ALKALINE PHOSPHATASE INCREASED
9%
WEIGHT GAIN
9%
NASAL CONGESTION
9%
Skin And Subcutaneous Tissue Disorders- Other, Rash Unspecified
9%
ABSOLUTE NEUTROPHIL COUNT DECREASED
9%
LIPASE INCREASED
9%
LYMPHOCYTE COUNT DECREASED
9%
HYPOCALCEMIA
9%
DRY SKIN
9%
Back Pain
9%
Creatinine Increased
9%
Papulopustular Rash
9%
Paresthesia
5%
Surgical & Medical Procedures - Other, Dental Extractions
5%
SPINAL CORD COMPRESSION
5%
INSOMNIA
5%
Investigations - Other, Eosinophilia
5%
Hypertension
5%
ANXIETY
5%
Sore Throat
5%
Musculoskeletal And Connective Tissue Disorders - Other, Extremity Cramps
5%
Myalgia
5%
Peripheral Sensory Neuropathy
5%
Peripheral Motor Neuropathy
5%
SINUS BRADYCARDIA
5%
Stomach Pain
5%
HEMATURIA
5%
TENDONITIS
5%
Gastrointestinal Disorders - Other, Buccal Cyst
5%
HYPERTHYROIDISM
5%
Hoarseness
5%
Gastrointestinal Disorders - Other, Dental Pain
5%
RASH
5%
DIFFICULTY WALKING, BACK PAIN, BOWEL/BLADDER URGENCY, LEGS GAVE OUT, AND PARESTHESIAS
5%
Gastrointestinal Disorders - Other, Stomatitis
5%
SUBJECT WAS ADMITTED TO THE HOSPITAL ON 10/24/20 WITH GRADE 2 WEIGHT LOSS THAT THE PHYSICIAN FELT NE
5%
Musculoskeletal And Connective Tissue Disorder - Other, Tendinitis
5%
Facial Pain
5%
HYPOMAGNESEMIA
5%
Allergic Rhinitis
5%
Activated Partial Thromboplastin Time Prolonged
5%
Leg Pain
5%
Muscle Weakness Lower Limb
5%
Muscle Weakness Upper Limb
5%
Psychiatric Disorders - Other, Mood Swings
5%
Scalp Lesion
5%
Scalp Pain
5%
Sinus Tachycardia
5%
Sinusitis
5%
Skin And Subcutaneous Tissue Disorders- Other, Blister/Bug Bite On Finger
5%
Skin And Subcutaneous Tissue Disorders- Other, Erythema
5%
Skin And Subcutaneous Tissue Disorders- Other, Sore On Lips
5%
Skin And Subcutaneous Tissue Disorders- Other, Transient Erythema
5%
Syncope
5%
Tachycardia
5%
Urine Discoloration
5%
JOINT RANGE OF MOTION DECREASED
5%
ANEMIA
5%
PARONYCHIA
5%
BRUISING
5%
SERUM AMYLASE INCREASED
5%
SKIN INFECTION
5%
HYPOALBUMINEMIA
5%
URINARY FREQUENCY
5%
URINARY URGENCY
5%
Behaviour Disturbance
5%
Breast Pain
5%
Conjunctivitis
5%
Creatine Phosphokinase Increased
5%
Ear And Labyrinth Disorders - Other, Impacted Cerumen
5%
Ear Pain
5%
Elevated Amylase
5%
Hypermagnesemia
5%
Hypotension
5%
Infections And Infestations - Other, Covid-19
5%
Infections And Infestations - Other, Gi Viral Infection
5%
Injury, Poisoning And Procedural Complications - Other, Ankle Injury
5%
Injury, Poisoning And Procedural Complications- Other, Scalp Laceration
5%
Investigations - Other, Increased Mean Corpuscular Volume
5%
Investigations - Other, International Normalized Ration Increased
5%
Laryngitis
5%
Localized Edema
5%
Lung Infection
5%
Metabolism And Nutrition Disorders - Other, Decreased Oral Intake
5%
Metabolism Other - Decreased Vitamin D
5%
Metbolism And Nutrition Disorders - Other, Hyperchloremia
5%
Mucositis Oral
5%
Neuropathy
5%
Periodontal Disease
5%
Rash Ezcematoid
5%
Skin And Subcutaneous Disorders - Other, Dry Skin Patches
5%
Skin And Subcutaneous Tissue Disorders - Other, Skin Color Change
5%
Skin And Subcutaneous Tissue Disorders - Other: Blue Lips (Not Cyanosis)
5%
Skin And Subcutaneous Tissue Disorders- Other, New Freckles/Moles
5%
Tooth Infection
5%
Joint Range Of Motion Decreased
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cohort B
Cohort A

Trial Design

1Treatment groups
Experimental Treatment
Group I: CabozantinibExperimental Treatment1 Intervention
This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion. Patients in GROUP D will have tumors with a RET fusion and have progressed on a selective RET TKI.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cabozantinib
2020
Completed Phase 2
~1760

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,944 Previous Clinical Trials
589,665 Total Patients Enrolled
ExelixisIndustry Sponsor
117 Previous Clinical Trials
19,448 Total Patients Enrolled
Alexander Drilon, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
3 Total Patients Enrolled

Media Library

Cabozantinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT01639508 — Phase 2
Non-Small Cell Lung Cancer Clinical Trial 2023: Cabozantinib Highlights & Side Effects. Trial Name: NCT01639508 — Phase 2
Non-Small Cell Lung Cancer Research Study Groups: Cabozantinib
Cabozantinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01639508 — Phase 2
~12 spots leftby Jul 2026